Mei Ri Jing Ji Xin Wen·2026-01-15 11:46Core Viewpoint - The company Sunflower (SZ300111) has been investigated by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, leading to the termination of its planned asset acquisition and restructuring efforts [1][4][7]. Group 1: Investigation and Regulatory Actions - On January 14, the CSRC issued a notice to Sunflower regarding an investigation into the company's information disclosure practices, resulting in a formal case being opened [1][4]. - The company was required to halt its planned acquisition of 100% of Zhangzhou Xipu Materials Technology Co., Ltd. and 40% of Zhejiang Beid Pharmaceutical Co., Ltd. due to the investigation [1][7]. - The Shenzhen Stock Exchange raised concerns about the actual production capacity of the acquisition target, Xipu Materials, prompting further scrutiny and a request for additional information from Sunflower [2][3]. Group 2: Financial Impact and Market Reaction - Following the announcement of the investigation, Sunflower's stock price fell to a limit down of 20%, with a trading volume of 1.22 million shares on January 15 [1][7]. - The company's stock price has halved from its peak of 10.28 yuan per share, reflecting significant market volatility and investor concern [1][8]. - Sunflower reported a revenue of 200 million yuan for the first three quarters of 2025, a year-on-year decrease of 12.09%, and a net profit of 1.31 million yuan, down 53.10% year-on-year, indicating financial pressures [1]. Group 3: Business Strategy and Future Outlook - Sunflower aimed to diversify into the semiconductor materials sector due to challenges in its core pharmaceutical business, which has been affected by price declines and competitive bidding risks [7][8]. - Despite the ongoing investigation, the company stated that its production and operational activities remain normal and that the termination of the restructuring will not significantly impact its operations [8].